Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Work In Process (2017 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Work In Process for 9 consecutive years, with $27.0 million as the latest value for Q4 2025.

  • Quarterly Work In Process rose 22.73% to $27.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.0 million through Dec 2025, up 22.73% year-over-year, with the annual reading at $27.0 million for FY2025, 22.73% up from the prior year.
  • Work In Process for Q4 2025 was $27.0 million at Ultragenyx Pharmaceutical, down from $29.2 million in the prior quarter.
  • The five-year high for Work In Process was $29.2 million in Q3 2025, with the low at $6.8 million in Q1 2021.
  • Average Work In Process over 5 years is $17.9 million, with a median of $18.7 million recorded in 2023.
  • The sharpest move saw Work In Process skyrocketed 76.75% in 2022, then decreased 21.77% in 2025.
  • Over 5 years, Work In Process stood at $10.5 million in 2021, then soared by 66.47% to $17.5 million in 2022, then grew by 7.85% to $18.9 million in 2023, then rose by 16.66% to $22.0 million in 2024, then grew by 22.73% to $27.0 million in 2025.
  • According to Business Quant data, Work In Process over the past three periods came in at $27.0 million, $29.2 million, and $19.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.